On Wednesday, the FDA approved an investigational device exemption (IDE) for Exact Sciences’ multi-cancer early detection (MCED) test, clearing the way for the test’s use in clinical studies. It’s a key milestone in our development of a rigorous and comprehensive MCED program. We look forward to the next phase, the launch of real-world evidence studies, in the coming months. The achievement wouldn’t be possible without the dedication, grit, and innovative spirit of the Exact Sciences team. Thank you for all you do.
This is great to hear - some devices really deserve to get out and into testing rapidly - this is one of them!
Congratulations on achieving this magnificent milestone! Cheers to a promising future for you and the patients you will soon serve!
Huge accomplishment! Congratulations, Exact Sciences Team. An IDE approval is not just a regulatory formality -- it is a crucial enabler of medical device #innovation, ensuring that new technologies are tested rigorously and safely before they can be widely used in #healthcare settings.
Congrats to the entire team on achieving this major milestone! Deb Kettner-Sieber, you are doing amazing work!
Congratulations to Exact Sciences on receiving FDA approval for your IDE! This is a monumental step forward in your MCED program. Kudos to the entire team for their dedication and innovation. Excited to see the impact of your upcoming real-world evidence studies!"
Congratulations to Exact Sciences. Fantastic news, and looking forward to seeing the impact and results from RWE studies.
Huge accomplishment. Congrats to the core team that worked so hard on this.
Congrats MCED team!
Let me know if I can help
Vice President and Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences
1moGrateful to all the Exact Sciences teams that made this milestone possible. FDA IDE approval enables us to begin evaluating our #MCED test in the next generation of our clinical studies.